Speak up ... if you dare: raising concerns about colleagues you suspect of bad practice is not easy in a working culture that views whistle-blowing as 'telling tales'.

S. Harrison

2003-01-15

Nursing Standard

Abstract:

What problem does this paper attempt to address?

Comparable antigen-specific T cell responses in vaccinees with diverse humoral immune responses after the primary and booster BBIBP-CorV vaccination

Dong Wei,Yingying Chen,Xiaoqi Yu,Yang-Dian Lai,Wenxin Xu,Ping Ji,Zhitao Yang,Erzhen Chen,Xinxin Zhang,Ying Wang

DOI: https://doi.org/10.1080/22221751.2022.2130101

2022-01-01

Emerging Microbes & Infections

Abstract:BBIBP-CorV exerts efficient protection against SARS-CoV-2 infection. However, waning vaccine-induced humoral immune responses after two-dose vaccination have significantly undermined durable immuno-protection. In this study, we have demonstrated that although anti-spike (S) antibody responses in BBIBP-CorV vaccinees exhibited three serotypes after 6 months, including de novo sero-negative, sero-positive, and sero-decay features, S-specific interferon-gamma release as well as Th1 cytokine production in CD4(+) and CD8(+) T cells were comparable, especially in vaccinees without detectable neutralizing antibodies. Notably, regardless of dramatic increases in humoral immunity after booster vaccination, T cell responses targeting S protein from either wild type or Omicron remained stable before and after booster vaccination in all three serotype vaccinees. No severe cases were observed even in the sero-decay group during the Omicron epidemic in Shanghai. Our results thus illustrate that unlike fluctuating humoral responses, viral-specific T cell responses are extremely stable after booster vaccination. Sustained T cell responses might be dedicated to the rapid restoration of antibody responses after booster vaccination.
Longitudinal Evaluation of Severe Acute Respiratory Syndrome Coronavirus 2 T-Cell Immunity Over 2 Years Following Vaccination and Infection

Anna Karina Juhl,Lisa Loksø Dietz,Ole Schmeltz Søgaard,Joanne Reekie,Henrik Nielsen,Isik Somuncu Johansen,Thomas Benfield,Lothar Wiese,Nina Breinholt Stærke,Tomas Østergaard Jensen,Rikke Olesen,Kasper Iversen,Kamille Fogh,Jacob Bodilsen,Lone Wulff Madsen,Susan Olaf Lindvig,Dorthe Raben,Sidsel Dahl Andersen,Astrid Korning Hvidt,Signe Rode Andreasen,Eva Anna Marianne Baerends,Jens Lundgren,Lars Østergaard,Martin Tolstrup,ENFORCE Study Group,J Lundgren,L J Østergaard,T Benfield,L Krohn-Dehli,D K Petersen,K Fogh,E H Mikkelsen,K Iversen,P Bek,V Klastrup,F Larsen,S H Rasmussen,M H Schleimann,S Schieber,N B Stærke,A Søndergaard,B Tarp,M Tousgaard,Y Yehdego,J Bodilsen,H Nielsen,K T Petersen,M R Juhl,R K Thisted,S F Caspersen,M Iversen,L S Knudsen,J L Meyerhoff,L G Sander,L Wiese,C Abildgaard,I K Holden,N E Johansen,I S Johansen,L Larsen,S O Lindvig,L W Madsen,A Øvrehus,N A Kruse,H Lomholdt,T G Krause,P Valentiner-Branth,B Søborg,T K Fischer,C Erikstrup,S R Ostrowski,M Tolstrup,O S Søgaard,D Raben,E Jylling,D Hougaard,S D Andersen,K Lykkegaard,S R Andreasen,E Baerends,L L Dietz,A K Hvidt,A K Juhl,R Olesen,K K Andersen,W Bannister,C Bjernved,T W Elsing,F V Esmann,M A Ghafari,E Gravholdt,S F Jakobsen,M L Jakobsen,C M Jensen,T Ø Jensen,D Kristensen,L R Kumar,C Matthews,N Normand,C Olsson,J Reekie,A Traytel,T Weide,A M Hvas,H Støvring,S Ostrowsky

DOI: https://doi.org/10.1093/infdis/jiae215

2024-09-23

Abstract:Background: Within a year of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, vaccines inducing a robust humoral and cellular immune response were implemented worldwide. However, emergence of novel variants and waning vaccine-induced immunity led to implementation of additional vaccine boosters. Methods: This prospective study evaluated the temporal profile of cellular and serological responses in a cohort of 639 SARS-CoV-2-vaccinated participants, of whom a large proportion experienced a SARS-CoV-2 infection. All participants were infection naïve at the time of their first vaccine dose. Proportions of SARS-CoV-2 spike-specific T cells were determined after each vaccine dose using the activation-induced marker assay, while levels of circulating SARS-CoV-2 antibodies were determined by the Meso Scale serology assay. Results: We found a significant increase in SARS-CoV-2 spike-specific CD4+ and CD8+ T-cell responses following the third dose of a SARS-CoV-2 messenger RNA vaccine as well as enhanced CD8+ T-cell responses after the fourth dose. Furthermore, increased age was associated with a poorer response. Finally, we observed that SARS-CoV-2 infection boosts both the cellular and humoral immune response, relative to vaccine-induced immunity alone. Conclusions: Our findings highlight the boosting effect on T-cell immunity of repeated vaccine administration. The combination of multiple vaccine doses and SARS-CoV-2 infections maintains population T-cell immunity, although with reduced levels in the elderly.
Durable T-cellular and humoral responses in SARS-CoV-2 hospitalized and community patients

Kristin G-I Mohn,Geir Bredholt,Fan Zhou,Anders Madsen,Therese B Onyango,Elisabeth B Fjelltveit,Sarah L Jalloh,Karl A Brokstad,Diego Cantoni,Martin Mayora-Neto,Nigel Temperton,Nina Langeland,Rebecca J Cox,Bergen COVID-19 research group

DOI: https://doi.org/10.1371/journal.pone.0261979

IF: 3.7

2022-02-22

PLoS ONE

Abstract:Background: Neutralizing antibodies are important for protection against the pandemic SARS-CoV-2 virus, and long-term memory responses determine the risk of re-infection or boosting after vaccination. T-cellular responses are considered important for partial protection against novel variants of concern. Methods: A prospective cohort of hospitalized (n = 14) and community (n = 38) patients with rt-PCR confirmed SARS-CoV-2 infection were recruited. Blood samples and clinical data were collected when diagnosed and at 6 months. Serum samples were analyzed for SARS-CoV-2-spike specific antibodies using ELISA (IgG, IgA, IgM), pseudotype neutralization and microneutralization assays. Peripheral blood mononuclear cells were investigated for virus-specific T-cell responses in the interferon-γ and interleukin-2 fluorescent-linked immunosorbent spot (FluroSpot) assay. Results: We found durable SARS-CoV-2 spike- and internal protein specific T-cellular responses in patients with persistent antibodies at 6 months. Significantly higher IL-2 and IFN-γ secreting T-cell responses as well as SARS-CoV-2 specific IgG and neutralizing antibodies were detected in hospitalized compared to community patients. The immune response was impacted by age, gender, comorbidity and severity of illness, reflecting clinical observations. Conclusions: SARS-CoV-2 specific T-cellular and antibody responses persisted for 6 months post confirmed infection. In previously infected patients, re-exposure or vaccination will boost long-term immunity, possibly providing protection against re-infection with variant viruses.
Robust Induction of B Cell and T Cell Responses by a Third Dose of Inactivated SARS-CoV-2 Vaccine

Yihao Liu,Qin Zeng,Caiguanxi Deng,Mengyuan Li,Liubing Li,Dayue Liu,Ming Liu,Xinyuan Ruan,Jie Mei,Ruohui Mo,Qian Zhou,Min Liu,Sui Peng,Ji Wang,Hui Zhang,Haipeng Xiao

DOI: https://doi.org/10.1038/s41421-022-00373-7

IF: 38.079

2022-01-01

Cell Discovery

Abstract:SARS-CoV-2 inactivated vaccines have shown remarkable efficacy in clinical trials, especially in reducing severe illness and casualty. However, the waning of humoral immunity over time has raised concern over the durability of immune memory following vaccination. Thus, we conducted a nonrandomized trial among the healthcare workers (HCWs) to investigate the long-term sustainability of SARS-CoV-2-specific B cells and T cells stimulated by inactivated vaccines and the potential need for a third booster dose. Although neutralizing antibodies elicited by the standard two-dose vaccination schedule dropped from a peak of 29.3 arbitrary units (AU)/mL to 8.8 AU/mL 5 months after the second vaccination, spike-specific memory B and T cells were still detectable, forming the basis for a quick recall response. As expected, the faded humoral immune response was vigorously elevated to 63.6 AU/mL by 7.2 folds 1 week after the third dose along with abundant spike-specific circulating follicular helper T cells in parallel. Meanwhile, spike-specific CD4(+) and CD8(+) T cells were also robustly elevated by 5.9 and 2.7 folds respectively. Robust expansion of memory pools by the third dose potentiated greater durability of protective immune responses. Another key finding in this trial was that HCWs with low serological response to two doses were not truly "non-responders" but fully equipped with immune memory that could be quickly recalled by a third dose even 5 months after the second vaccination. Collectively, these data provide insights into the generation of long-term immunological memory by the inactivated vaccine, which could be rapidly recalled and further boosted by a third dose.
Cellular and humoral immune responses and breakthrough infections after three SARS-CoV-2 mRNA vaccine doses

Patricia Almendro-Vázquez,Marta Chivite-Lacaba,Alberto Utrero-Rico,Cecilia González-Cuadrado,Rocio Laguna-Goya,Miguel Moreno-Batanero,Laura Sánchez-Paz,Joanna Luczkowiak,Nuria Labiod,María Dolores Folgueira,Rafael Delgado,Estela Paz-Artal

DOI: https://doi.org/10.3389/fimmu.2022.981350

IF: 7.3

2022-08-17

Frontiers in Immunology

Abstract:Background SARS-CoV-2 vaccination has proven the most effective measure to control the COVID-19 pandemic. Booster doses are being administered with limited knowledge on their need and effect on immunity. Objective To determine the duration of specific T cells, antibodies and neutralization after 2-dose vaccination, to assess the effect of a third dose on adaptive immunity and to explore correlates of protection against breakthrough infection. Methods 12-month longitudinal assessment of SARS-CoV-2-specific T cells, IgG and neutralizing antibodies triggered by 2 BNT162b2 doses followed by a third mRNA-1273 dose in a cohort of 77 healthcare workers: 17 with SARS-CoV-2 infection prior to vaccination (recovered) and 60 naïve. Results Peak levels of cellular and humoral response were achieved 2 weeks after the second dose. Antibodies declined thereafter while T cells reached a plateau 3 months after vaccination. The decline in neutralization was specially marked in naïve individuals and it was this group who benefited most from the third dose, which resulted in a 20.9-fold increase in neutralization. Overall, recovered individuals maintained higher levels of T cells, antibodies and neutralization 1 to 6 months post-vaccination than naïve. Seventeen asymptomatic or mild SARS-CoV-2 breakthrough infections were reported during follow-up, only in naïve individuals. This viral exposure boosted adaptive immunity. High peak levels of T cells and neutralizing antibodies 15 days post-vaccination associated with protection from breakthrough infections. Conclusion Booster vaccination in naïve individuals and the inclusion of viral antigens other than spike in future vaccine formulations could be useful strategies to prevent SARS-CoV-2 breakthrough infections.

immunology
Serological assessment of the durability of vaccine-mediated protection against SARS-CoV-2 infection

John T. Bates,Seth T. Lirette,Andrew P. Farmer,Michael A. Bierdeman,Kristina B. Seyfarth,Dallas R. Ederer,Denise D. Montgomery,Grace C. Burnett,Amanda T. Pham,Gailen D. Marshall

DOI: https://doi.org/10.1080/21645515.2024.2308375

2024-02-17

Human Vaccines & Immunotherapeutics

Abstract:Virus-neutralizing antibodies are often accepted as a correlate of protection against infection, though questions remain about which components of the immune response protect against SARS-CoV-2 infection. In this small observational study, we longitudinally measured spike receptor binding domain (RBD)-specific and nucleocapsid (NP)-specific serum IgG in a human cohort immunized with the Pfizer BNT162b2 vaccine. NP is not encoded in the vaccine, so an NP-specific response is serological evidence of natural infection. A greater than fourfold increase in NP-specific antibodies was used as the serological marker of infection. Using the RBD-specific IgG titers prior to seroconversion for NP, we calculated a protective threshold for RBD-specific IgG. On average, the RBD-specific IgG response wanes below the protective threshold 169 days following vaccination. Many participants without a history of a positive test result for SARS-CoV-2 infection seroconverted for NP-specific IgG. As a group, participants who seroconverted for NP-specific IgG had significantly higher levels of RBD-specific IgG following NP-seroconversion. RBD-specific IgG titers may serve as one correlate of protection against SARS-CoV-2 infection. These titers wane below the proposed protective threshold approximately six months following immunization. Based on serological evidence of infection, the frequency of breakthrough infections and consequently the level of SARS-CoV-2-specific immunity in the population may be higher than what is predicted based on the frequency of documented infections.

immunology,biotechnology & applied microbiology
Evaluation of post-vaccination immunoglobulin G antibodies and T-cell immune response after inoculation with different types and doses of SARS-CoV-2 vaccines: A retrospective cohort study

Rami H. Al-Rifai,Farida Alhosani,Rowan Abuyadek,Shereen Atef,James G. Donnelly,Andrea Leinberger-Jabari,Luai A. Ahmed,Basel Altrabulsi,Adnan Alatoom,Ahmed R. Alsuwaidi,Laila AbdelWareth

DOI: https://doi.org/10.3389/fmed.2022.1092646

IF: 3.9

2023-01-10

Frontiers in Medicine

Abstract:Introduction The induction and speed of production of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) immune biomarkers may vary by type and number of inoculated vaccine doses. This study aimed to explore variations in SARS-CoV-2 anti-spike (anti-S), anti-nucleocapsid (anti-N), and neutralizing immunoglobulin G (IgG) antibodies, and T-cell response by type and number of SARS-CoV-2 vaccine doses received. Methods In a naturally exposed and SARS-CoV-2–vaccinated population, we quantified the anti-S, anti-N, and neutralizing IgG antibody concentration and assessed T-cell response. Data on socio-demographics, medical history, and history of SARS-CoV-2 infection and vaccination were collected. Furthermore, nasal swabs were collected to test for SARS-CoV-2 infection. Confounder-adjusted association between having equal or more than a median concentration of the three IgG antibodies and T-cell response by number and type of the inoculated vaccines was quantified. Results We surveyed 952 male participants with a mean age of 35.5 years ± 8.4 standard deviations. Of them, 52.6% were overweight/obese, and 11.7% had at least one chronic comorbidity. Of the participants, 1.4, 0.9, 20.2, 75.2, and 2.2% were never vaccinated, primed with only one dose, primed with two doses, boosted with only one dose, and boosted with two doses, respectively. All were polymerase chain reaction-negative to SARS-CoV-2. BBIBP-CorV (Sinopharm) was the most commonly used vaccine (92.1%), followed by rAd26-S + rAd5-S (Sputnik V Gam-COVID-Vac) (1.5%) and BNT162b2 (Pfizer-BioNTech) (0.3%). Seropositivity to anti-S, anti-N, and neutralizing IgG antibodies was detected in 99.7, 99.9, and 99.3% of the study participants, respectively. The T-cell response was detected in 38.2% of 925 study participants. Every additional vaccine dose was significantly associated with increased odds of having ≥median concentration of anti-S [adjusted odds ratio (aOR), 1.34; 95% confidence interval (CI): 1.02–1.76], anti-N (aOR, 1.35; 95% CI: 1.03–1.75), neutralizing IgG antibodies (aOR, 1.29; 95% CI: 1.00–1.66), and a T-cell response (aOR, 1.48; 95% CI: 1.12–1.95). Compared with boosting with only one dose, boosting with two doses was significantly associated with increased odds of having ≥median concentration of anti-S (aOR, 13.8; 95% CI: 1.78–106.5), neutralizing IgG antibodies (aOR, 13.2; 95% CI: 1.71–101.9), and T-cell response (aOR, 7.22; 95% CI: 1.99–26.5) although not with anti-N (aOR, 0.41; 95% CI: 0.16–1.08). Compared with priming and subsequently boosting with BBIBP-CorV, all participants who were primed with BBIBP-CorV and subsequently boosted with BNT162b2 had ≥median concentration of anti-S and neutralizing IgG antibodies and 14.6-time increased odds of having a T-cell response (aOR, 14.63; 95% CI: 1.78–120.5). Compared with priming with two doses, boosting with the third dose was not associated, whereas boosting with two doses was significantly associated with having ≥median concentration of anti-S (aOR, 14.20; 95% CI: 1.85–109.4), neutralizing IgG (aOR, 13.6; 95% CI: 1.77–104.3), and T-cell response (aOR, 7.62; 95% CI: 2.09–27.8). Conclusion Achieving and maintaining a high blood concentration of protective immune biomarkers that predict vaccine effectiveness is very critical to limit transmission and contain outbreaks. In this study, boosting with only one dose or with only BBIBP-CorV after priming with BBIBP-CorV was insufficient, whereas boosting with two doses, particularly boosting with the mRNA-based vaccine, was shown to be associated with having a high concentration of anti-S, anti-N, and neutralizing IgG antibodies and producing an efficient T-cell response.

medicine, general & internal
Dynamic SARS-CoV-2-specific B-cell and T-cell Responses Following Immunization with an Inactivated COVID-19 Vaccine

Yuxin Chen,Shengxia Yin,Xin Tong,Yue Tao,Jun Ni,Jie Pan,Ming Li,Yawen Wan,Minxin Mao,Yali Xiong,Xiaomin Yan,Yue Yang,Rui Huang,Chao Wu,Han Shen

DOI: https://doi.org/10.1016/j.cmi.2021.10.006

IF: 13.31

2021-01-01

Clinical Microbiology and Infection

Abstract:Objective: The dynamic adaptive immune responses elicited by the inactivated virus vaccine CoronaVac remain elusive. Methods: In a prospective cohort of 100 healthcare professionals naive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) who received two doses of CoronaVac, we analysed SARS-CoV-2-specific humoral and cellular responses at four different timepoints, including before vaccination (T1), 2 weeks after the first dose (T2), 2 weeks after the booster dose (T3), and 8-10 weeks after the booster dose (T4). SARS-CoV-2-specific antibodies, serum neutralizing activities, peripheral B cells, CD4(+) and CD8(+) T cells and their memory subsets were simultaneously measured in this cohort. Results: SARS-CoV-2 spike-specific IgG responses reached a peak (geometric mean titre (GMT) 54827, 30969-97065) after two doses and rapidly declined (GMT 502, 212-1190) at T4, whereas suboptimal IgA responses were detected (GMT 5, 2-9). Spike-specific circulating B cells (0.60%, 0.46-0.73% of total B cells) and memory B cells (1.18%, 0.92-1.44% of total memory B cells) were effectively induced at T3 and sustained over time (0.33%, 0.23-0.43%; 0.87%, 0.05-1.67%, respectively). SARS-CoV-2-specific circulating CD4(+) T cells (0.57%, 0.47-0.66%) and CD8(+) T cells (1.29%, 1.04-1.54%) were detected at T3. At T4, 0.78% (0.43-1.20%) of memory CD4+ T cells and 0.68% (0.29-1.30%) of memory CD8(+) T cells were identified as SARS-CoV-2-specific, while 0.62% (0.51-0.75%) of CD4(+) T cells and 0.47% (0.38-0.58%) of CD8(+) T cells were SARS-CoV-2-specific terminally differentiated effector memory cells. Furthermore, age and interval between doses affected the magnitude of CoronaVac-induced immune responses. SARS-CoV-2 memory CD4(+) T cells were strongly associated with both receptor binding domain (RBD)-specific memory B cells (r 0.87, p <0.0001) and SARS-CoV-2-specific memory CD8(+) T cells (r 0.48, p <0.0001). Conclusions: CoronaVac induced robust circulating and memory B cell and T cell responses. Our study offers new insight into the underlying immunobiology of inactivated virus vaccines in humans and may have implications for vaccine strategies in the future. (C) 2021 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Evolution of antibody immunity to SARS-CoV-2

Christian Gaebler,Zijun Wang,Julio C. C. Lorenzi,Frauke Muecksch,Shlomo Finkin,Minami Tokuyama,Alice Cho,Mila Jankovic,Dennis Schaefer-Babajew,Thiago Y. Oliveira,Melissa Cipolla,Charlotte Viant,Christopher O. Barnes,Yaron Bram,Gaëlle Breton,Thomas Hägglöf,Pilar Mendoza,Arlene Hurley,Martina Turroja,Kristie Gordon,Katrina G. Millard,Victor Ramos,Fabian Schmidt,Yiska Weisblum,Divya Jha,Michael Tankelevich,Gustavo Martinez-Delgado,Jim Yee,Roshni Patel,Juan Dizon,Cecille Unson-O’Brien,Irina Shimeliovich,Davide F. Robbiani,Zhen Zhao,Anna Gazumyan,Robert E. Schwartz,Theodora Hatziioannou,Pamela J. Bjorkman,Saurabh Mehandru,Paul D. Bieniasz,Marina Caskey,Michel C. Nussenzweig

DOI: https://doi.org/10.1038/s41586-021-03207-w

IF: 64.8

2021-01-18

Nature

Abstract:Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has infected 78 million individuals and is responsible for over 1.7 million deaths to date. Infection is associated with development of variable levels of antibodies with neutralizing activity that can protect against infection in animal models1,2. Antibody levels decrease with time, but the nature and quality of the memory B cells that would be called upon to produce antibodies upon re-infection has not been examined. Here we report on the humoral memory response in a cohort of 87 individuals assessed at 1.3 and 6.2 months after infection. We find that IgM, and IgG anti-SARS-CoV-2 spike protein receptor binding domain (RBD) antibody titres decrease significantly with IgA being less affected. Concurrently, neutralizing activity in plasma decreases by fivefold in pseudotype virus assays. In contrast, the number of RBD-specific memory B cells is unchanged. Memory B cells display clonal turnover after 6.2 months, and the antibodies they express have greater somatic hypermutation, increased potency and resistance to RBD mutations, indicative of continued evolution of the humoral response. Analysis of intestinal biopsies obtained from asymptomatic individuals 4 months after the onset of coronavirus disease-2019 (COVID-19), using immunofluorescence, or polymerase chain reaction, revealed persistence of SARS-CoV-2 nucleic acids and immunoreactivity in the small bowel of 7 out of 14 volunteers. We conclude that the memory B cell response to SARS-CoV-2 evolves between 1.3 and 6.2 months after infection in a manner that is consistent with antigen persistence.

multidisciplinary sciences
Structure of a surface polysaccharide from Acinetobacter baumannii O16.

S. Haseley,H. J. Diggle,S. Wilkinson

DOI: https://doi.org/10.1016/0008-6215(96)00196-6

IF: 2.975

1996-10-31

Carbohydrate Research

Abstract:
Hybrid adaptive immunity to SARS-CoV-2 protects against breakthrough infection after COVID-19 vaccination in ALSPAC participants.

Holly Baum,Marianna Santopaolo,Ore Francis,Emily Milowdowski,Katrina Entwistle,Elizabeth Oliver,Benjamin Hitchings,Divya Diamond,Amy Thomas,Ruth Mitchell,Milla Kibble,Kapil Gupta,Natalie Di Bartolo,Paul Klenerman,Anthony Brown,Begonia Morales-Aza,Jennifer Oliver,Imre Berger,Ashley Mark Toye,Adam Finn,Anu Goenka,Andrew D. Davidson,Susan Ring,Lynn Molloy,Melanie Lewcock,Kate Northstone,Firona Roth,Nicholas J Timpson,Linda Wooldridge,Alice Halliday,Laura Rivino

DOI: https://doi.org/10.1101/2024.06.14.24308948

2024-08-08

Abstract:Immunological memory to vaccination and viral infection involves coordinated action of B and T-cells, thus integrated analysis of these two components is critical for understanding their contributions to protection against breakthrough infections (BI). We investigated cellular and humoral immune responses to SARS-CoV-2 infection and/or COVID-19 vaccination in participants from the Avon Longitudinal Study of Parents and Children (ALSPAC). The magnitude of antibody and T-cell responses following the second vaccine dose was associated with protection against BI in participants with a history of SARS-CoV-2 infection (cases), but not in infection-naive controls. Youdens index thresholds for protection against BI were calculated for all immune measures. Anti-Spike IgG (>666.4 BAU/mL) and anti-nucleocapsid N pan Ig (>0.1332 BAU/mL) thresholds combined were 100% sensitive and 83% specific for cases without BI over 8-months follow-up. Collectively these results point to the superior protective effect of hybrid immunity and have implications for the design of next-generation COVID-19 vaccines.

Infectious Diseases (except HIV/AIDS)
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Jennifer M Dan,Jose Mateus,Yu Kato,Kathryn M Hastie,Esther Dawen Yu,Caterina E Faliti,Alba Grifoni,Sydney I Ramirez,Sonya Haupt,April Frazier,Catherine Nakao,Vamseedhar Rayaprolu,Stephen A Rawlings,Bjoern Peters,Florian Krammer,Viviana Simon,Erica Ollmann Saphire,Davey M Smith,Daniela Weiskopf,Alessandro Sette,Shane Crotty,Jennifer M. Dan,Kathryn M. Hastie,Caterina E. Faliti,Sydney I. Ramirez,Stephen A. Rawlings,Davey M. Smith

DOI: https://doi.org/10.1126/science.abf4063

IF: 56.9

2021-02-05

Science

Abstract:Variable memory Immune memory against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) helps to determine protection against reinfection, disease risk, and vaccine efficacy. Using 188 human cases across the range of severity of COVID-19, Dan et al. analyzed cross-sectional data describing the dynamics of SARS-CoV-2 memory B cells, CD8 + T cells, and CD4 + T cells for more than 6 months after infection. The authors found a high degree of heterogeneity in the magnitude of adaptive immune responses that persisted into the immune memory phase to the virus. However, immune memory in three immunological compartments remained measurable in greater than 90% of subjects for more than 5 months after infection. Despite the heterogeneity of immune responses, these results show that durable immunity against secondary COVID-19 disease is a possibility for most individuals. Science , this issue p. eabf4063

multidisciplinary sciences
Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine

Chiara Agrati,Concetta Castilletti,Delia Goletti,Alessandra Sacchi,Veronica Bordoni,Davide Mariotti,Stefania Notari,Giulia Matusali,Silvia Meschi,Linda Petrone,Alessandra Aiello,Saeid Najafi Fard,Chiara Farroni,Francesca Colavita,Daniele Lapa,Sara Leone,Alessandro Agresta,Maria Capobianchi,Giuseppe Ippolito,Francesco Vaia,Vincenzo Puro,Eleonora Cimini,Eleonora Tartaglia,Rita Casetti,Germana Grassi,Flavia Cristofanelli,Andrea Capri,Annapaola Santoro,Nicoletta Orchi,Aurora Bettini,Massimo Francalancia,Eliana Specchiarello,

DOI: https://doi.org/10.1038/s41598-022-07741-z

IF: 4.6

2022-04-23

Scientific Reports

Abstract:Abstract Vaccine is the main public health measure to reduce SARS-CoV-2 transmission and hospitalization, and a massive scientific effort worldwide resulted in the rapid development of effective vaccines. This work aimed to define the dynamics and persistence of humoral and cell-mediated immune response in Health Care Workers who received a two-dose BNT162b2-mRNA vaccination. Serological response was evaluated by quantifying anti-RBD and neutralizing antibodies while cell-mediated response was performed by a whole blood test quantifying Th1 cytokines (IFN-γ, TNF-α, IL-2) produced in response to Spike peptides. BNT162b2-mRNA vaccine induced both humoral and cell-mediated immune response against Spike in all HCW early after the second dose. After 12 weeks from vaccination, the titer of anti-RBD antibodies as well as their neutralization function decreased while the Spike-specific T-cells persisted at the same level as soon after vaccine boost. Of note, a correlation between cellular and humoral response persevered, suggesting the persistence of a coordinated immune response. The long lasting cell-mediated immune response after 3 months from vaccination highlight its importance in the maintaining of specific immunity able to expand again to fight eventual new antigen encountering.

multidisciplinary sciences
Longitudinal study of immunity to SARS‐CoV2 in ocrelizumab‐treated MS patients up to 2 years after COVID‐19 vaccination

Ilya Kister,Ryan Curtin,Amanda L. Piquet,Tyler Borko,Jinglan Pei,Barbara L Banbury,Tamar E. Bacon,Angie Kim,Michael Tuen,Yogambigai Velmurugu,Samantha Nyovanie,Sean Selva,Marie I. Samanovic,Mark J. Mulligan,Yury Patskovsky,Jessica Priest,Mark Cabatingan,Ryan C. Winger,Michelle Krogsgaard,Gregg J. Silverman

DOI: https://doi.org/10.1002/acn3.52081

IF: 5.43

2024-05-08

Annals of Clinical and Translational Neurology

Abstract:Objectives (1) To plot the trajectory of humoral and cellular immune responses to the primary (two‐dose) COVID‐19 mRNA series and the third/booster dose in B‐cell‐depleted multiple sclerosis (MS) patients up to 2 years post‐vaccination; (2) to identify predictors of immune responses to vaccination; and (3) to assess the impact of intercurrent COVID‐19 infections on SARS CoV‐2‐specific immunity. Methods Sixty ocrelizumab‐treated MS patients were enrolled from NYU (New York) and University of Colorado (Anschutz) MS Centers. Samples were collected pre‐vaccination, and then 4, 12, 24, and 48 weeks post‐primary series, and 4, 12, 24, and 48 weeks post‐booster. Binding anti‐Spike antibody responses were assessed with multiplex bead‐based immunoassay (MBI) and electrochemiluminescence (Elecsys®, Roche Diagnostics), and neutralizing antibody responses with live‐virus immunofluorescence‐based microneutralization assay. Spike‐specific cellular responses were assessed with IFNγ/IL‐2 ELISpot (Invitrogen) and, in a subset, by sequencing complementarity determining regions (CDR)‐3 within T‐cell receptors (Adaptive Biotechnologies). A linear mixed‐effect model was used to compare antibody and cytokine levels across time points. Multivariate analyses identified predictors of immune responses. Results The primary vaccination induced an 11‐ to 208‐fold increase in binding and neutralizing antibody levels and a 3‐ to 4‐fold increase in IFNγ/IL‐2 responses, followed by a modest decline in antibody but not cytokine responses. Booster dose induced a further 3‐ to 5‐fold increase in binding antibodies and 4‐ to 5‐fold increase in IFNγ/IL‐2, which were maintained for up to 1 year. Infections had a variable impact on immunity. Interpretation Humoral and cellular benefits of COVID‐19 vaccination in B‐cell‐depleted MS patients were sustained for up to 2 years when booster doses were administered.

neurosciences,clinical neurology
Early human B cell signatures of the primary antibody response to mRNA vaccination

Lela Kardava,Nicholas Rachmaninoff,William W. Lau,Clarisa M. Buckner,Krittin Trihemasava,Jana Blazkova,Felipe Lopes de Assis,Wei Wang,Xiaozhen Zhang,Yimeng Wang,Chi-I Chiang,Sandeep Narpala,Genevieve E. McCormack,Can Liu,Catherine A. Seamon,Michael C. Sneller,Sarah O’Connell,Yuxing Li,Adrian B. McDermott,Tae-Wook Chun,Anthony S. Fauci,John S. Tsang,Susan Moir

DOI: https://doi.org/10.1073/pnas.2204607119

IF: 11.1

2022-06-27

Proceedings of the National Academy of Sciences

Abstract:Messenger RNA (mRNA) vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are highly effective at inducing protective immunity. However, weak antibody responses are seen in some individuals, and cellular correlates of immunity remain poorly defined, especially for B cells. Here we used unbiased approaches to longitudinally dissect primary antibody, plasmablast, and memory B cell (MBC) responses to the two-dose mRNA-1273 vaccine in SARS-CoV-2–naive adults. Coordinated immunoglobulin A (IgA) and IgG antibody responses were preceded by bursts of spike-specific plasmablasts after both doses but earlier and more intensely after dose 2. While antibody and B cell cellular responses were generally robust, they also varied within the cohort and decreased over time after a dose-2 peak. Both antigen-nonspecific postvaccination plasmablast frequency after dose 1 and their spike-specific counterparts early after dose 2 correlated with subsequent antibody levels. This correlation between early plasmablasts and antibodies remained for titers measured at 6 months after vaccination. Several distinct antigen-specific MBC populations emerged postvaccination with varying kinetics, including two MBC populations that correlated with 2- and 6-month antibody titers. Both were IgG-expressing MBCs: one less mature, appearing as a correlate after the first dose, while the other MBC correlate showed a more mature and resting phenotype, emerging as a correlate later after dose 2. This latter MBC was also a major contributor to the sustained spike-specific MBC response observed at month 6. Thus, these plasmablasts and MBCs that emerged after both the first and second doses with distinct kinetics are potential determinants of the magnitude and durability of antibodies in response to mRNA-based vaccination.

multidisciplinary sciences
Long-Lasting Enhanced Cytokine Responses Following SARS-CoV-2 BNT162b2 mRNA Vaccination

Georgiana Cabău,Medeea Badii,Andreea M Mirea,Orsolya I Gaal,Liesbeth van Emst,Radu A Popp,Tania O Crișan,Leo A B Joosten

DOI: https://doi.org/10.3390/vaccines12070736

2024-07-03

Abstract:The mRNA vaccine against COVID-19 protects against severe disease by the induction of robust humoral and cellular responses. Recent studies have shown the capacity of some vaccines to induce enduring non-specific innate immune responses by the induction of trained immunity, augmenting protection against unrelated pathogens. This study aimed to assess whether the mRNA vaccine BNT162b2 can induce lasting non-specific immune responses in myeloid cells following a three-dose vaccination scheme. In a sample size consisting of 20 healthy individuals from Romania, we assessed inflammatory proteins using the Olink® Target 96 Inflammation panel, as well as ex vivo cytokine responses following stimulations with unrelated PRR ligands. We assessed the vaccine-induced non-specific systemic inflammation and functional adaptations of myeloid cells. Our results revealed the induction of a stimulus- and cytokine-dependent innate immune memory phenotype that became apparent after the booster dose and was maintained eight months later in the absence of systemic inflammation.
Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

Jeffrey Seow,Carl Graham,Blair Merrick,Sam Acors,Suzanne Pickering,Kathryn J. A. Steel,Oliver Hemmings,Aoife O’Byrne,Neophytos Kouphou,Rui Pedro Galao,Gilberto Betancor,Harry D. Wilson,Adrian W. Signell,Helena Winstone,Claire Kerridge,Isabella Huettner,Jose M. Jimenez-Guardeño,Maria Jose Lista,Nigel Temperton,Luke B. Snell,Karen Bisnauthsing,Amelia Moore,Adrian Green,Lauren Martinez,Brielle Stokes,Johanna Honey,Alba Izquierdo-Barras,Gill Arbane,Amita Patel,Mark Kia Ik Tan,Lorcan O’Connell,Geraldine O’Hara,Eithne MacMahon,Sam Douthwaite,Gaia Nebbia,Rahul Batra,Rocio Martinez-Nunez,Manu Shankar-Hari,Jonathan D. Edgeworth,Stuart J. D. Neil,Michael H. Malim,Katie J. Doores

DOI: https://doi.org/10.1038/s41564-020-00813-8

IF: 28.3

2020-10-26

Nature Microbiology

Abstract:Antibody responses to SARS-CoV-2 can be detected in most infected individuals 10–15 d after the onset of COVID-19 symptoms. However, due to the recent emergence of SARS-CoV-2 in the human population, it is not known how long antibody responses will be maintained or whether they will provide protection from reinfection. Using sequential serum samples collected up to 94 d post onset of symptoms (POS) from 65 individuals with real-time quantitative PCR-confirmed SARS-CoV-2 infection, we show seroconversion (immunoglobulin (Ig)M, IgA, IgG) in >95% of cases and neutralizing antibody responses when sampled beyond 8 d POS. We show that the kinetics of the neutralizing antibody response is typical of an acute viral infection, with declining neutralizing antibody titres observed after an initial peak, and that the magnitude of this peak is dependent on disease severity. Although some individuals with high peak infective dose (ID50 > 10,000) maintained neutralizing antibody titres >1,000 at >60 d POS, some with lower peak ID50 had neutralizing antibody titres approaching baseline within the follow-up period. A similar decline in neutralizing antibody titres was observed in a cohort of 31 seropositive healthcare workers. The present study has important implications when considering widespread serological testing and antibody protection against reinfection with SARS-CoV-2, and may suggest that vaccine boosters are required to provide long-lasting protection.

microbiology
Lasting antibody and T cell responses to SARS-CoV-2 in COVID-19 patients three months after infection

Xiao-Lin Jiang,Guo-Lin Wang,Xiang-Na Zhao,Fei-Hu Yan,Lin Yao,Zeng-Qiang Kou,Sheng-Xiang Ji,Xiao-Li Zhang,Cun-Bao Li,Li-Jun Duan,Yan Li,Yu-Wen Zhang,Qing Duan,Tie-Cheng Wang,En-Tao Li,Xiao Wei,Qing-Yang Wang,Xue-Feng Wang,Wei-Yang Sun,Yu-Wei Gao,Dian-Min Kang,Ji-Yan Zhang,Mai-Juan Ma

DOI: https://doi.org/10.1038/s41467-021-21155-x

IF: 16.6

2021-02-09

Nature Communications

Abstract:Abstract The dynamics, duration, and nature of immunity produced during SARS-CoV-2 infection are still unclear. Here, we longitudinally measured virus-neutralising antibody, specific antibodies against the spike (S) protein, receptor-binding domain (RBD), and the nucleoprotein (N) of SARS-CoV-2, as well as T cell responses, in 25 SARS-CoV-2-infected patients up to 121 days post-symptom onset (PSO). All patients seroconvert for IgG against N, S, or RBD, as well as IgM against RBD, and produce neutralising antibodies (NAb) by 14 days PSO, with the peak levels attained by 15–30 days PSO. Anti-SARS-CoV-2 IgG and NAb remain detectable and relatively stable 3–4 months PSO, whereas IgM antibody rapidly decay. Approximately 65% of patients have detectable SARS-CoV-2-specific CD4 + or CD8 + T cell responses 3–4 months PSO. Our results thus provide critical evidence that IgG, NAb, and T cell responses persist in the majority of patients for at least 3–4 months after infection.

multidisciplinary sciences
Systemic SARS-CoV-2-specific antibody responses to infection and to COVID-19 and BCG vaccination

Juana Claus,Thijs ten Doesschate,Esther Taks,Priya Debisarun,Gaby Smits,Rob van Binnendijk,Fiona van der Klis,Lilly M. Verhagen,Marien I. de Jonge,Marc J.M. Bonten,Mihai G. Netea,Janneke H. H. M. van de Wijgert

DOI: https://doi.org/10.1101/2024.01.24.24301644

2024-01-24

Abstract:SARS-CoV-2 infections elicit antibodies against the viral spike (S) and nucleocapsid (N) proteins; COVID-19 vaccines against the S-protein only. The BCG-Corona trial, initiated in March 2020 in SARS-CoV-2-naïve Dutch healthcare workers, captured several epidemic peaks and the introduction of COVID-19 vaccines during the one-year follow-up. We assessed determinants of systemic anti-S1 and anti-N immunoglobulin type G (IgG) responses using trial data. Participants were randomized to BCG or placebo vaccination, reported daily symptoms, SARS-CoV-2 test results, and COVID-19 vaccinations, and donated blood for SARS-CoV-2 serology at two time points. In the 970 participants, anti-S1 geometric mean antibody concentrations (GMCs) were much higher than anti-N GMCs. Anti-S1 GMCs significantly increased with increasing number of immune events (SARS-CoV-2 infection or COVID-19 vaccination): 104.7 international units (IU)/ml, 955.0 IU/ml, and 2290.9 IU/ml for one, two, and three immune events, respectively (p<0.001). In adjusted multivariable linear regression models, anti-S1 and anti-N log concentrations were significantly associated with infection severity, and anti-S1 log concentration with COVID-19 vaccine type/dose. In univariable models, anti-N log concentration was also significantly associated with acute infection duration, and severity and duration of individual symptoms. Antibody concentrations were not associated with Long COVID or long-term loss of smell/taste.

Epidemiology
Longitudinal analysis of B- and T-cell responses to SARS-CoV-2 recombinant S-protein vaccine S-268019-b in phase 1/2 priming and booster study

Masaya Fujitani,Xiuyuan Lu,Ryo Shinnakasu,Takeshi Inoue,Yujiro Kidani,Naomi M Seki,Satoru Ishida,Shungo Mitsuki,Takeshi Ishihara,Miwa Aoki,Akio Suzuki,Koji Takahashi,Masahiro Takayama,Takeshi Ota,Satoshi Iwata,Risa Yokokawa Shibata,Takuhiro Sonoyama,Mari Ariyasu,Ayumi Kitano,Tommy Terooatea,Jordan Kelly Villa,Kazuo Yamashita,Sho Yamasaki,Tomohiro Kurosaki,Shinya Omoto

DOI: https://doi.org/10.1101/2024.10.01.24314659

2024-10-03

Abstract:The durability of vaccine-induced immune memory to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is crucial for preventing infection, especially severe disease. This follow-up report from a phase 1/2 study of S-268019-b (a recombinant spike protein vaccine) after homologous booster vaccination confirms its long-term safety, tolerability, and immunogenicity. Booster vaccination with S-268019-b resulted in an enhancement of serum neutralizing antibody (NAb) titers and a broad range of viral neutralization. Single-cell immune profiling revealed persistent and mature antigen-specific memory B cells and T follicular helper cells, with increased B-cell receptor diversity. The expansion of B- and T-cell repertoires and presence of cross-reactive NAbs targeting conserved epitopes within the receptor-binding domain following a booster accounted for the broad-spectrum neutralizing activity. These findings highlight the potential of S-268019-b to provide broad and robust protection against a range of SARS-CoV-2 variants, addressing a critical challenge in the ongoing fight against coronavirus disease 2019 (COVID-19).

Speak up ... if you dare: raising concerns about colleagues you suspect of bad practice is not easy in a working culture that views whistle-blowing as 'telling tales'.

Comparable antigen-specific T cell responses in vaccinees with diverse humoral immune responses after the primary and booster BBIBP-CorV vaccination

Longitudinal Evaluation of Severe Acute Respiratory Syndrome Coronavirus 2 T-Cell Immunity Over 2 Years Following Vaccination and Infection

Durable T-cellular and humoral responses in SARS-CoV-2 hospitalized and community patients

Robust Induction of B Cell and T Cell Responses by a Third Dose of Inactivated SARS-CoV-2 Vaccine

Cellular and humoral immune responses and breakthrough infections after three SARS-CoV-2 mRNA vaccine doses

Serological assessment of the durability of vaccine-mediated protection against SARS-CoV-2 infection

Evaluation of post-vaccination immunoglobulin G antibodies and T-cell immune response after inoculation with different types and doses of SARS-CoV-2 vaccines: A retrospective cohort study

Dynamic SARS-CoV-2-specific B-cell and T-cell Responses Following Immunization with an Inactivated COVID-19 Vaccine

Evolution of antibody immunity to SARS-CoV-2

Structure of a surface polysaccharide from Acinetobacter baumannii O16.

Hybrid adaptive immunity to SARS-CoV-2 protects against breakthrough infection after COVID-19 vaccination in ALSPAC participants.

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine

Longitudinal study of immunity to SARS‐CoV2 in ocrelizumab‐treated MS patients up to 2 years after COVID‐19 vaccination

Early human B cell signatures of the primary antibody response to mRNA vaccination

Long-Lasting Enhanced Cytokine Responses Following SARS-CoV-2 BNT162b2 mRNA Vaccination

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

Lasting antibody and T cell responses to SARS-CoV-2 in COVID-19 patients three months after infection

Systemic SARS-CoV-2-specific antibody responses to infection and to COVID-19 and BCG vaccination

Longitudinal analysis of B- and T-cell responses to SARS-CoV-2 recombinant S-protein vaccine S-268019-b in phase 1/2 priming and booster study